Printer Friendly

NIH FASTER Study Concludes First Trimester Screening Is Better Than Second Trimester Down Syndrome Screening.

CHAPEL HILL, N.C. -- First trimester Nuchal Translucency/freeBeta/PAPP-A prenatal screening for Down syndrome has been confirmed by the NIH FASTER Study (NEJM 2005;353:2001) to be more effective than second trimester screening methods. Dr. Joe Leigh Simpson, author of the editorial (NEJM 2005; 353:19) concluded "First- trimester screening is thus clearly superior to screening in the second trimester. The gap would probably widen if the assessment of the nasal bone becomes incorporated in risk estimates". First trimester NT/freeBeta/PAPP-A is provided by GeneCare and was recognized as an option for all pregnant women by the American College of Obstetricians and Gynecologists (ACOG), the American College of Medical Genetics (ACMG) and the NIH in 2004.

The study was performed on 33,546 patients at 10 weeks 3 days - 13 weeks 6 days. Nuchal Translucency (NT) ultrasound measurements were combined with freeBeta hCG and PAPP-A blood proteins tests. In the study first trimester NT/freeBeta/PAPP-A screening detected 86% of Down syndrome pregnancies at a 5% false positive rate. These results confirmed 23 previously published studies of over 230,000 patients. The accepted detection rate for Down syndrome is 91% at 5% false positive rate based on all studies. GeneCare also incorporates Nasal Bone (NB) which raises detection to 95% at 2% false positive rate. First Trimester NT/NB/freeBeta/PAPP-A screening offers the earliest and safest prenatal screening for Down syndrome, trisomy 18/13, 40% of fetal heart defects, many other anomalies and perinatal risk.

The real significance of this consensus is that NT/NB/freeBeta/PAPP-A screening provides the most effective pregnancy management in the first trimester to improve birth defects detection and provide patients with the earliest and safest options. NT/freeBeta/PAPP-A, referred to as Early Screen(R), is available to all pregnant patients throughout the USA and is provided by sonographers and physicians who have Fetal Medicine Foundation special training and certificates for nuchal translucency measurement.

Patients have responded through published surveys that they strongly prefer first trimester screening for privacy and improved healthcare. It is now appropriate to offer NT/NB/freeBeta/PAPP-A prenatal screening to all low risk patients as well as to increased risk patients who decline amniocentesis. Patients should be aware that prenatal screening is not a substitute for diagnostic amniocentesis or CVS testing.

GeneCare provides FMF USA NT and NB training courses to physicians, sonographers and other prenatal healthcare providers through nonprofit courses listed at www.genecare.com. To find an FMF NT and NB certificate provider of Early Screen(R) call GeneCare at (800) 277-4363 or email at info@genecare.com.
COPYRIGHT 2005 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 
Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Nov 30, 2005
Words:435
Previous Article:Webcast Alert: Adams Express Co. & Petroleum & Resources Corp. Presentation at Informed Investors Closed End Fund On-line Forum to be Webcast on...
Next Article:North Texas Hospital New Home to American Cancer Society Memorial Brick Garden; Ribbon Cutting Ceremony November 18, 2005.
Topics:


Related Articles
Cocaine mothers imperil babies' brains.
Schizophrenia: promising drug ... and infectious clues.
American Heart Association.
Novel technologies for in vivo imaging.
In certain circumstances, women in prenatal care would not rule out having an abortion in the future.
Fetal lead exposure at each stage of pregnancy as a predictor of infant mental development.
PAHs and cognitive impairment: prenatal exposure catches up with toddlers.
Women & pregnancy.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters